Lys Therapeutics is a biotechnology company developing first-in-class monoclonal antibodies to treat patients suffering from neurodegenerative and neurovascular diseases with high unmet medical needs. Its lead candidate, LYS241, is a vascular-targeting immunotherapy with a unique mode of action counteracting neuroinflammation & BBB disruption by blocking the pathological interaction between tPA and NMDA receptors. This mechanism is central to the pathogenesis of several major neurological disorders, including Parkinson’s disease, ischemic stroke, and other neuro-inflammatory conditions.

With operations in Lyon and Caen (France), and strategic collaborations with international research institutions, Lys Therapeutics is advancing a robust and versatile pipeline, supported by prestigious funding partners including The Michael J. Fox Foundation, Bpifrance, and private investors.

Lys Therapeutics' approach of targeting neuroinflammation to combat neurodegeneration represents a promising avenue in the search for effective treatments for these debilitating disorders.

More information on lystherapeutics.com

Lys Therapeutics

Org chart

Teams

Offices